Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2016

01-02-2016 | Clinical trial

Lin28A and androgen receptor expression in ER−/Her2+ breast cancer

Authors: Honghong Shen, Yong Yang, Lin Zhao, Jinyang Yuan, Yun Niu

Published in: Breast Cancer Research and Treatment | Issue 1/2016

Login to get access

Abstract

The aim of this study was to examine the expression of Lin28A and androgen receptor (AR) in ER−/Her2+ breast cancer, and to research the association of Lin28A and AR co-expression status with patients’ prognosis. The expression of Lin28A and AR in formalin-fixed and paraffin-embedded surgical sections from 305 patients with ER−/Her2+ breast cancer was analyzed by immunohistochemistry, and the co-expression patterns in breast cancer cells were investigated by immunofluorescent staining. The impact of the expression of Lin28A and AR in prognosis was also assessed by the Kaplan–Meier, univariate, and multivariate logistic regression models. This study included 305 cases ER−/Her2+ breast cancer patients. Lin28A and AR were expressed in 240 cases (78.7 %) and 220 cases (72.1 %), respectively. Lin28A tended to be higher in AR-positive patients (75.0 %). Lin28A and AR co-expression (Lin28+/AR+) was significantly associated with high tumor grade (G3) (p = 0.023) and high Ki67 index (p = 0.020). The mRNA and protein expression levels of Lin28A and AR were higher in MDA-MB-453 cells (ER−/Her2+) than in the MDA-MB-231 cells (ER−/Her2−). In univariate analysis, Lin28A+/AR+ was significant risk factors associated with unfavorable OS (p = 0.049) and RFS (p = 0.019). Kaplan–Meier analysis showed that Lin28A+/AR+ expression showed lower RFS rates compared with Lin28A−/AR+ (p = 0.043) and Lin28A−/AR− patients(p = 0.019). Multivariate cox model showed that Lin28A+/AR+ remained an independent negative prognostic factor for RFS. Our study showed that Lin28A and AR co-expressed in ER−/Her-2+ breast cancer and correlated with poor prognosis. The possibility that Lin28A may drive AR expression via a positive feedback mechanism remains to be tested.
Literature
1.
Oh DS, Troester MA, Usary J et al (2006) Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 24:1656–1664CrossRefPubMed
2.
Ibrahim EM, Kazkaz GA, Al-Mansour MM, Al-Foheidi ME (2015) The predictive and vprognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis. Breast Cancer Res Treat 152:463–476CrossRefPubMed
3.
Joensuu H, Isola J, Lundin M et al (2003) Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 9:923–930PubMed
4.
Tolaney SM, Barry WT, Dang CT, Yardley DA et al (2015) Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positivebreast cancer. N Engl J Med 372:134–141CrossRefPubMedPubMedCentral
5.
Viswanathan SR, Powers JT, Einhorn W et al (2009) Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 41:843–848CrossRefPubMedPubMedCentral
6.
Iliopoulos D, Hirsch H, Struhl K (2009) An epigenetic switch involving NFkappaB, Lin28, Let-7 microRNA and IL6 links inflammation to cell transformation. Cell 139:693–706CrossRefPubMedPubMedCentral
7.
Peng S, Maihle N, Huang Y (2010) Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer. Oncogene 29:2153–2159CrossRefPubMed
8.
Huang Y (2012) A mirror of two faces: Lin28 as a master regulator of both miRNA and mRNA. Wiley Interdiscip Rev RNA 3:483–494CrossRefPubMed
9.
10.
11.
Malik F, Korkaya H, Clouthier SG, Wicha MS (2012) Lin28 and HER2: two stem cell regulators conspire to drive aggressive breast cancer. Cell Cycle 2012(11):2780–2781CrossRef
12.
Feng C, Neumeister V, Ma W et al (2012) Lin28 regulates HER2 and promotes malignancy through multiple mechanisms. Cell Cycle 11:2486–2494CrossRefPubMed
13.
Agoff SN, Swanson PE, Linden H et al (2003) Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 120:725–731CrossRefPubMed
14.
Niemeier LA, Dabbs DJ, Beriwal S et al (2010) Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 23:205–212CrossRefPubMed
15.
16.
Tummala R, Nadiminty N, Lou W et al (2013) Lin28 promotes growth of prostate cancer cells and activates the androgen receptor. Am J Pathol 183:288–295CrossRefPubMedPubMedCentral
17.
Xie R, Wang Y, Nie W et al (2014) Lin28B expression correlates with aggressive clinicopathological characteristics in breast invasive ductal carcinoma. Cancer Biother Radiopharm 29:215–220CrossRefPubMedPubMedCentral
18.
Moinfar F, Okcu M, Tsybrovskyy O et al (2003) Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 98:703–711CrossRefPubMed
19.
Park S, Koo J, Park HS et al (2010) Expression of androgen receptors in primary breast cancer. Ann Oncol 21:488–492CrossRefPubMed
20.
Yu Q, Niu Y, Liu N et al (2011) Expression of androgen receptor in breast cancer and its significance as a prognostic factor. Ann Oncol 22:1288–1294CrossRefPubMed
21.
Bianchi S, Caini S, Paglierani M et al (2015) Accuracy and reproducibility of HER2 status in breast cancer using immunohistochemistry: a quality control study in Tuscany evaluating the impact of updated 2013 ASCO/CAP recommendations. Pathol Oncol Res 21:477–485CrossRefPubMed
22.
King CE, Wang L, Winograd R et al (2011) LIN28B fosters colon cancer migration, invasion and transformation through let-7-dependent and -independent mechanisms. Oncogene 30:4185–4193CrossRefPubMedPubMedCentral
23.
Hamano R, Miyata H, Yamasaki M et al (2012) High expression of Lin28 is associated with tumour aggressiveness and poor prognosis of patients in oesophagus cancer. Br J Cancer 106:1415–1423CrossRefPubMedPubMedCentral
24.
Balzer E, Moss EG (2007) Localization of the developmental timing regulator Lin28 to mRNP complexes, P-bodies and stress granules. RNA Biol 4:16–25CrossRefPubMed
25.
Samaan NA, Buzdar AU, Aldinger KA et al (1981) Estrogen receptor: a prognostic factor in breast cancer. Cancer 47:554–560CrossRefPubMed
26.
Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502CrossRefPubMed
27.
Schippinger W, Regitnig P, Dandachi N et al (2006) Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer. Virchows Arch 449:24–30CrossRefPubMed
28.
29.
30.
Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697CrossRefPubMed
31.
Yang YL, Fan Y, Lang RG et al (2012) Genetic heterogeneity of HER2 in breast cancer: impact on HER2 testing and its clinicopathologic significance. Breast Cancer Res Treat 134:1095–1102CrossRefPubMed
32.
Lordick F (2011) Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer. Future Oncol 7:187–199CrossRefPubMed
33.
34.
Gijsen M, King P, Perera T et al (2010) HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol 8:e1000563CrossRefPubMedPubMedCentral
35.
Zhang S, Huang WC, Li P et al (2011) Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 17:461–469CrossRefPubMed
36.
37.
Sakurai M, Miki Y, Masuda M et al (2012) LIN28: a regulator of tumor suppressing activity of let-7 microRNA in human breast cancer. J Steroid Biochem Mol Biol 131:101–106CrossRefPubMed
38.
Naderi A, Hughes-Davies L (2008) A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 10:542–548CrossRefPubMedPubMedCentral
39.
Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, Gerald WL (2006) An estrogen receptor–negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25:3994–4008CrossRefPubMed
40.
Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable Her-2-positive breast cancer. N Engl J Med 353:1673–1684CrossRefPubMed
Metadata
Title
Lin28A and androgen receptor expression in ER−/Her2+ breast cancer
Authors
Honghong Shen
Yong Yang
Lin Zhao
Jinyang Yuan
Yun Niu
Publication date
01-02-2016
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-3744-9

Other articles of this Issue 1/2016

Breast Cancer Research and Treatment 1/2016 Go to the issue

Epidemiology

iPrevent®: a tailored, web-based, decision support tool for breast cancer risk assessment and management

Clinical trial

A phase II trial of dose-dense (biweekly) paclitaxel plus carboplatin as neoadjuvant chemotherapy for operable breast cancer

Clinical trial

Detection of disseminated tumor cells from the bone marrow of patients with early breast cancer is associated with high 21-gene recurrence score

Clinical trial

Breast cancer screening using tomosynthesis in combination with digital mammography compared to digital mammography alone: a cohort study within the PROSPR consortium

Clinical trial

Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study

Letter to the Editor

Comments on ‘Brief screening of patients with distressing fear of recurrence in breast cancer survivors’ by Akechi et al., Breast Cancer Res Treat, 2015, 153(2): pp. 475–476
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits